NEW YORK (Reuters Health)—Tocilizumab improves remission rates and slows disease progression in patients with early rheumatoid arthritis (RA), a new randomized controlled trial demonstrates. Tocilizumab was effective both on its own and when combined with methotrexate, Dr. Gerd R. Burmester of Charite Medical University of Berlin and his colleagues found. Tocilizumab, an interleukin-6 (IL-6) blocker,…
Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer
NEW YORK (Reuters Health)—Methotrexate appears to increase the risk of recurrent nonmelanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA), according to a retrospective study. “We have known for some time that several of the immunosuppressive agents used to treat RA and inflammatory bowel disease (IBD) are also associated with an increased risk of…
German Registry Evaluates Systemic Psoriasis Treatments
The German Psoriasis Registry, PsoBest, found conventional systemic and biologic drugs for psoriasis demonstrated relative safety from serious adverse events in patients between January 2008–December 2012…
Auto-Injectable Methotrexate: New Treatment Option for RA
Methotrexate has long been a cornerstone of therapy in rheumatoid arthritis. Two new, injectable methotrexate products may help some RA patients for whom oral methotrexate is not as effective or causes adverse effects. Rasuvo and Otrexup are prefilled, auto-injection devices that allow patients to give themselves subcutaneous injections of methotrexate without having to use a…
Methotrexate Halt Feasible in Some Etanercept RA Responders
NEW YORK (Reuters Health)—Certain rheumatoid arthritis (RA) patients doing well on etanercept and methotrexate may be able to quit the latter agent if they have tolerability problems, according to an open-label Canadian study. In a Sept. 11 online paper in Rheumatology, Dr. Boulos Haraoui, of the University of Montreal, and colleagues noted that although combination…
New Labeling for Infused Golimumab; Phase 3 Trial for Romosozumab Promising
The FDA has approved new labeling for infused golimumab to include measures of mental and physical health. Plus romosozumab meets primary endpoints in postmenopausal women with osteoporosis during a Phase 3 trial…
Self-Monitoring of RA Treatment May Lead to Fewer Office Visits
NEW YORK (Reuters Health)—Self-monitoring of methotrexate therapy may curb healthcare utilization in rheumatoid arthritis (RA) and psoriatic arthritis, according to a new trial. The study indicates “that this novel model of care led to significant reductions in outpatient visits to the (clinical nurse specialist) and a reduction in visits to the GP, while maintaining the…
Early, Aggressive Therapy for RA May Result in Cost Savings Long Term
By considering the long-term damage from early, aggressive rheumatoid arthritis, researchers in the UK were able to develop a model demonstrating the long-term cost effectiveness of more aggressive combination therapies v. short-term treatments…
Brentuximab Vedotin Enters Phase 2 Trials & More
Phase 2 clinical trials have begun to assess the safety of brentuximab vedotin for the treatment of SLE. Also, the FDA is reviewing an application for a once-daily tofacitinib citrate tablet to treat RA…
Certolizumab Pegol Effective for Treating Rheumatoid Arthritis
NEW YORK (Reuters Health)—Certolizumab pegol, a humanized anti-TNF antibody fragment conjugated to polyethylene glycol, is effective for treating early rheumatoid arthritis (RA) with poor prognostic factors, according to results from the C-OPERA study. Certolizumab is approved in the U.S. and other countries for treating inflammatory diseases, including RA, but its effectiveness in methotrexate-naïve early RA…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 15
- Next Page »